Akcea Therapeutics, Inc. (AKCA)
Stock Price:
$14.13 USD
0.23 (1.65%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.43B |
| Revenue (ttm) |
340.80M |
| Net Income (ttm) |
-29.27M |
| Shares Out |
101.51M |
| EPS (ttm) |
-0.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$14.13 |
| Previous Close |
$13.90 |
| Change ($) |
0.23 |
| Change (%) |
1.65% |
| Day's Open |
14.03 |
| Day's Range |
13.72 - 14.24 |
| Day's Volume |
207,187 |
| 52-Week Range |
8.00 - 25.66 |
More Stats
| Market Cap |
1.43B |
| Enterprise Value |
1.03B |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
101.51M |
| Float |
17.68M |
| EPS (basic) |
-0.27 |
| EPS (diluted) |
-0.45 |
| FCF / Share |
0.99 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
7.00% |
| Payout Ratio |
n/a |
| Shares Short |
3.14M |
| Short Ratio |
11.25 |
| Short % of Float |
24.91% |
| Beta |
1.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
14.29 |
| PS Ratio |
4.21 |
| PB Ratio |
3.08 |
| Revenue |
340.80M |
| Operating Income |
-33.39M |
| Net Income |
-29.27M |
| Free Cash Flow |
100.35M |
| Net Cash |
407.40M |
| Net Cash / Share |
4.01 |
| Gross Margin |
54.50% |
| Operating Margin |
-9.80% |
| Profit Margin |
-8.60% |
| FCF Margin |
29.45% |
| ROA |
-4.10% |
| ROE |
-6.51% |
| ROIC |
-14.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.00*
(105.24% upside)
Low
20.0
Current: 14.13
High
41.0
Target: 29.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 489 | 64.87 | 43.40 | - | - | - |
| Revenue Growth | 653.15% | 49.46% | - | - | - | - |
| Gross Profit | 473 | 53.13 | 43.40 | - | - | - |
| Operating Income | 38.07 | -231 | -120 | -83.51 | -61.44 | -30.02 |
| Net Income | 40.77 | -226 | -122 | -83.22 | -61.42 | -30.02 |
| Shares Outstanding | 92.92 | 81.37 | 15.75 | 28.88 | 28.88 | 28.88 |
| Earnings Per Share | 0.29 | -2.87 | -3.08 | - | - | - |
| Operating Cash Flow | 224 | -203 | -36.19 | -55.36 | -44.28 | -29.90 |
| Capital Expenditures | -1.60 | -1.12 | -0.01 | -0.18 | -0.01 | - |
| Free Cash Flow | 222 | -204 | -36.20 | -55.54 | -44.29 | -29.90 |
| Cash & Equivalents | 464 | 253 | 260 | 7.86 | 64.31 | 0.00 |
| Total Debt | 14.25 | 4.44 | - | - | - | - |
| Net Cash / Debt | 449 | 248 | 260 | 7.86 | 64.31 | 0.00 |
| Assets | 599 | 365 | 269 | 10.68 | 66.07 | - |
| Liabilities | 56.25 | 88.54 | 101 | 28.43 | 10.80 | - |
| Book Value | 543 | 277 | 168 | -17.75 | 55.27 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Akcea Therapeutics, Inc. |
| Country |
United States |
| Employees |
294 |
| CEO |
Damien McDevitt |
Stock Information
| Ticker Symbol |
AKCA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AKCA |
| IPO Date |
July 14, 2017 |
Description
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.